UNIVERSITY OF WASHINGTON MED CTR
- Type
- Teaching hospital
- Where
- Seattle, WA
- Medicare CCN
- 500008
- Received
- $47,370,301 in 2,336 records, 2020 ($6,189,141 general, $41,181,159 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 380 | $6,189,141 |
| 2020 | Research payment | 1,956 | $41,181,159 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 1,956 | $41,181,159 |
| Grant | 85 | $3,444,416 |
| Royalty or License | 91 | $1,010,526 |
| Education | 66 | $594,448 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 47 | $431,184 |
| Consulting Fee | 19 | $412,703 |
| Space rental or facility fees (teaching hospital only) | 59 | $221,397 |
| Gift | 9 | $47,246 |
| Charitable Contribution | 4 | $27,218 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Philips North America LLC | $26,880 | Research payment | Cash or cash equivalent | (6260) Ingenia 3 0T R5 Device, Neurology | 2020 | |
| 2020-12-31 | Allergan, Inc. | $17,303 | Research payment | In-kind items and services | AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety o | 2020 | |
| 2020-12-31 | Intuitive Surgical, Inc. | $16,840 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-12-31 | Medartis Inc. | $16,365 | Gift (9 payments) | In-kind items and services | APTUS Device, ORTHO | 2020 | |
| 2020-12-31 | Intuitive Surgical, Inc. | $16,117 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-12-31 | Intuitive Surgical, Inc. | $13,080 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-12-31 | Philips North America LLC | $8,960 | Research payment | Cash or cash equivalent | (6260) Ingenia 3 0T R5 Device, Neurology | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $7,936 | Research payment | In-kind items and services | AIDA HD Connect Device, OR1 | Develop remote robotically-assisted insertion of a flexible cystoscope / Improve algorithms for complete human bladder m | 2020 |
| 2020-12-31 | VASCULAR SOLUTIONS, INC. | $7,826 | Research payment | In-kind items and services | Interventional Products Device, Interventional Access | CTO-PCI | 2020 |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $6,845 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for t | 2020 |
| 2020-12-31 | Intuitive Surgical, Inc. | $6,250 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $5,230 | Research payment | In-kind items and services | A Phase 1b/2, Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or with | 2020 | |
| 2020-12-31 | Intuitive Surgical, Inc. | $5,000 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-12-31 | VASCULAR SOLUTIONS, INC. | $4,284 | Research payment | In-kind items and services | Interventional Products Device, Interventional Access | CTO-PCI | 2020 |
| 2020-12-31 | Acerta Pharma LLC | $3,927 | Research payment | In-kind items and services | CALQUENCE Drug, Oncology | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2020 |
| 2020-12-31 | Acerta Pharma LLC | $3,791 | Research payment | In-kind items and services | CALQUENCE Drug, Oncology | A Proof of Concept Study of the Combination of ACP196 and ACP319 in Subjects with Bcell Malignancies | 2020 |
| 2020-12-31 | Stryker Corporation | $3,780 | Gift | In-kind items and services | SURG - REMB Device, SURGICAL | 2020 | |
| 2020-12-31 | VASCULAR SOLUTIONS, INC. | $3,777 | Research payment | In-kind items and services | Interventional Products Device, Interventional Access | CTO-PCI | 2020 |
| 2020-12-31 | Intuitive Surgical, Inc. | $2,720 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-12-31 | Intuitive Surgical, Inc. | $2,720 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-12-31 | Intuitive Surgical, Inc. | $2,680 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-12-31 | Roche Diagnostics Corporation | $2,017 | Education | In-kind items and services | MD cobas Instruments and Reagents Device, Molecular Diagnostics | 2020 | |
| 2020-12-31 | Intuitive Surgical, Inc. | $2,010 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-12-31 | Allergan, Inc. | $2,000 | Research payment | Cash or cash equivalent | A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients with Open-Angle Glaucoma or Ocular Hyperte | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $1,794 | Research payment | In-kind items and services | A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-Small Cell Lung Cancer whose Disease has Progr | 2020 | |
| 2020-12-31 | Roche Diagnostics Corporation | $1,672 | Education | In-kind items and services | MD cobas Instruments and Reagents Device, Molecular Diagnostics | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $1,631 | Research payment | Cash or cash equivalent | UW2017MRIPR8471061MossaBasha | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $1,389 | Research payment | Cash or cash equivalent | UW2020MRIPR1315MossaBasha | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $1,031 | Research payment | Cash or cash equivalent | UWash2019MRIPR1047MossaBasha | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $1,021 | Research payment | In-kind items and services | Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum Resistant Ovaria | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $938 | Research payment | Cash or cash equivalent | UWashIPR10162016MossaBasha | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $439 | Research payment | In-kind items and services | MEDI9447 CD73 Solid Tmr-D6070C00001 Phase 1 Clinical Trial | 2020 | |
| 2020-12-31 | Linvatec Corporation | $400 | Grant | In-kind items and services | HALL POWER Device, ORTHOPEDIC SURGERY | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $332 | Research payment | Cash or cash equivalent | UWash2020MRIPR1106MossaBasha | 2020 | |
| 2020-12-31 | Stryker Corporation | $311 | Gift | Cash or cash equivalent | NONE Device, NONE | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $237 | Research payment | In-kind items and services | CALQUENCE Drug, Oncology | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2020 |
| 2020-12-31 | Stryker Corporation | $129 | Gift | Cash or cash equivalent | NONE Device, NONE | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $73 | Research payment | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | Forxiga HF-D1699C00001 HF rEF Outcome study | 2020 |
| 2020-12-31 | Stryker Corporation | $2 | Gift | Cash or cash equivalent | NONE Device, NONE | 2020 | |
| 2020-12-30 | ABBVIE INC. | $12,881 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-431 | 2020 |
| 2020-12-30 | ABBVIE INC. | $4,845 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-430 | 2020 |
| 2020-12-30 | Penumbra, Inc. | $1,827 | Research payment | Cash or cash equivalent | Artemis Device, Neurosurgery | MIND | 2020 |
| 2020-12-30 | ABBVIE INC. | $476 | Research payment | Cash or cash equivalent | M14-239 | 2020 | |
| 2020-12-29 | Genentech, Inc. | $26,979 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PH 2 RANDOMIZED POC STUDY OF PCV IN 1L MELANOMA | 2020 |
| 2020-12-29 | Genentech, Inc. | $16,623 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PH IA IB PERSONALIZED CANCER VACCINE ATEZOLIZUMABB | 2020 |
| 2020-12-29 | Bayer Healthcare Pharmaceuticals Inc. | $5,060 | Research payment | Cash or cash equivalent | Stivarga Drug, Oncology | BAY73-4506 phase I HCC 1st line combination PD1inh | 2020 |
| 2020-12-29 | Genentech, Inc. | $1,133 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PH IA IB PERSONALIZED CANCER VACCINE ATEZOLIZUMABB | 2020 |
| 2020-12-29 | Incyte Corporation | $673 | Research payment | Cash or cash equivalent | Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanc | 2020 | |
| 2020-12-29 | Genentech, Inc. | $115 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PH 2 RANDOMIZED POC STUDY OF PCV IN 1L MELANOMA | 2020 |
| 2020-12-28 | Cook Biotech Incorporated | $17,090 | Research payment | Cash or cash equivalent | 2020 | ||
| 2020-12-28 | Janssen Research & Development, LLC | $2,276 | Research payment | Cash or cash equivalent | A Phase 2 Study of ARN-509 in Active Surveillance Patients | 2020 | |
| 2020-12-24 | Blueprint Medicines Corporation | $74,384 | Research payment | Cash or cash equivalent | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2020 | |
| 2020-12-24 | Daiichi Sankyo Inc. | $9,906 | Research payment | Cash or cash equivalent | Enhertu Drug, Oncology | 2020 | |
| 2020-12-24 | Daiichi Sankyo Inc. | $7,429 | Research payment | Cash or cash equivalent | Enhertu Drug, Oncology | 2020 | |
| 2020-12-24 | Amgen Inc. | $2,752 | Research payment | Cash or cash equivalent | AMG 510_P1/2 Monotherapy NSCLC/CRC/Tumor Agnostic_20170543 | 2020 | |
| 2020-12-24 | Amgen Inc. | $2,304 | Research payment | Cash or cash equivalent | AMG 510_P1/2 Monotherapy NSCLC/CRC/Tumor Agnostic_20170543 | 2020 | |
| 2020-12-24 | Intercept Pharmaceuticals, Inc. | $921 | Research payment | Cash or cash equivalent | 1009742 | 2020 | |
| 2020-12-24 | Allergan, Inc. | $750 | Research payment | Cash or cash equivalent | AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety o | 2020 | |
| 2020-12-24 | Daiichi Sankyo Inc. | $502 | Research payment | Cash or cash equivalent | Enhertu Drug, Oncology | 2020 | |
| 2020-12-23 | SEAGEN INC. | $65,326 | Research payment | Cash or cash equivalent | A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies | 2020 | |
| 2020-12-23 | ABBVIE INC. | $23,260 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | M14-358 | 2020 |
| 2020-12-23 | SEAGEN INC. | $22,246 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2020 |
| 2020-12-23 | Deciphera Pharmaceuticals Inc. | $3,464 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2020 |
| 2020-12-23 | Gilead Sciences, Inc. | $3,114 | Research payment | Cash or cash equivalent | Harvoni Drug, HCV | A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for H | 2020 |
| 2020-12-23 | Deciphera Pharmaceuticals Inc. | $1,675 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2020 |
| 2020-12-23 | Medtronic Vascular, Inc. | $1,156 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Resolute Device, Stents | 2020 | |
| 2020-12-23 | Allergan, Inc. | $750 | Research payment | Cash or cash equivalent | AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety o | 2020 | |
| 2020-12-22 | Insulet Corporation | $37,093 | Research payment | Cash or cash equivalent | Omnipod Device, Insulin Pump | Evaluating the Safety and Effectiveness of the Omnipod Horizon Automated Glucose Control System in Patients with Type 1 | 2020 |
| 2020-12-22 | Incyte Corporation | $7,715 | Research payment | Cash or cash equivalent | A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma | 2020 | |
| 2020-12-22 | Genentech, Inc. | $2,390 | Research payment | Cash or cash equivalent | ROZLYTREK Biological, BioOncology | STARTRK 2 RXDX 101 02 | 2020 |
| 2020-12-22 | Incyte Corporation | $1,346 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepat | 2020 | |
| 2020-12-22 | Incyte Corporation | $1,144 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepat | 2020 | |
| 2020-12-22 | Incyte Corporation | $946 | Research payment | Cash or cash equivalent | A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma | 2020 | |
| 2020-12-22 | Incyte Corporation | $499 | Research payment | Cash or cash equivalent | A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma | 2020 | |
| 2020-12-21 | SANOFI US SERVICES INC. | $100,000 | Research payment | Cash or cash equivalent | IHME Epi Project Q4 2020 | 2020 | |
| 2020-12-21 | SANOFI US SERVICES INC. | $50,000 | Research payment | Cash or cash equivalent | IHME Epi Project Q4 2020 | 2020 | |
| 2020-12-21 | SANOFI US SERVICES INC. | $50,000 | Research payment | Cash or cash equivalent | IHME Epi Project Q4 2020 | 2020 | |
| 2020-12-21 | SANOFI US SERVICES INC. | $50,000 | Research payment | Cash or cash equivalent | IHME Epi Project Q4 2020 | 2020 | |
| 2020-12-21 | Biogen, Inc. | $45,000 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-12-21 | Genentech, Inc. | $39,493 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | ATEZOLIZUMAB IN MUSCLE INVASIVE BLADDER CANCER MIBC | 2020 |
| 2020-12-21 | SANOFI US SERVICES INC. | $17,764 | Research payment | Cash or cash equivalent | A Phase 1/2 Study for the Safety, Efficacy, Pharmacokinetic and Pharmacodynamics Evaluation of SAR439859, Administered O | 2020 | |
| 2020-12-21 | Janssen Research & Development, LLC | $5,014 | Research payment | Cash or cash equivalent | A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with | 2020 | |
| 2020-12-21 | SANOFI US SERVICES INC. | $3,180 | Research payment | Cash or cash equivalent | SARCLISA Biological, Oncology | A Phase 1/2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab (SAR6509 | 2020 |
| 2020-12-21 | Blueprint Medicines Corporation | $1,704 | Research payment | Cash or cash equivalent | BLU-667-1101 | 2020 | |
| 2020-12-21 | Genentech, Inc. | $889 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | BTK FIH P1A | 2020 |
| 2020-12-21 | SANOFI US SERVICES INC. | $857 | Research payment | Cash or cash equivalent | A Phase 1/2 Study for the Safety, Efficacy, Pharmacokinetic and Pharmacodynamics Evaluation of SAR439859, Administered O | 2020 | |
| 2020-12-21 | Bracco Diagnostics Inc. | $777 | Research payment | Cash or cash equivalent | MultiHance Drug, Diagnostic Imaging | An Autopsy Tissue Study For Quantification Of Gadolinium Levels And Histhopathological Changes From Subjects Who Receive | 2020 |
| 2020-12-21 | Ivoclar Vivadent, Inc. | $769 | Research payment | Cash or cash equivalent | sthetic & AdheseUniv Clinical Evaluation of Variolink Eersal For Posterior Ceramic Restoration Cementation. | 2020 | |
| 2020-12-21 | SANOFI US SERVICES INC. | $698 | Research payment | Cash or cash equivalent | SARCLISA Biological, Oncology | A Phase 1/2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab (SAR6509 | 2020 |
| 2020-12-21 | Boston Scientific Corporation | $252 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | REPRISE III | 2020 |
| 2020-12-21 | Eli Lilly and Company | $9 | Research payment | In-kind items and services | A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY OF LY3471851 (NKTR 358) IN ADULTS WITH SYSTEMIC LUPUS ERYT | 2020 | |
| 2020-12-18 | Becton, Dickinson and Company | $24,438 | Royalty or License | Cash or cash equivalent | BD Pharmingen Device, Cell Analysis | 2020 | |
| 2020-12-18 | Abbott Laboratories | $5,603 | Research payment | Cash or cash equivalent | FlexAbility Ablation Catheter Device, Cardiac Arrhythmias and Heart Failure | FLExAbility Sensor Enabled Substrate Targeted Ablation for the Reduction of Ventricular Tachycardia (LESS-VT) Study | 2020 |
| 2020-12-18 | VENTANA MEDICAL SYSTEMS, INC. | $3,569 | Research payment | In-kind items and services | DISCOVERY/SPRING IUO/RUO PLATFORMS & REAGENTS Device, Tissue Diagnostics | RD002198 | 2020 |
| 2020-12-18 | Janssen Research & Development, LLC | $2,083 | Research payment | Cash or cash equivalent | Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus | 2020 | |
| 2020-12-18 | Abbott Laboratories | $1,905 | Research payment | Cash or cash equivalent | FlexAbility Ablation Catheter Device, Cardiac Arrhythmias and Heart Failure | FLExAbility Sensor Enabled Substrate Targeted Ablation for the Reduction of Ventricular Tachycardia (LESS-VT) Study | 2020 |
| 2020-12-18 | Becton, Dickinson and Company | $807 | Royalty or License | Cash or cash equivalent | BD Pharmingen Device, Cell Analysis | 2020 | |
| 2020-12-18 | Becton, Dickinson and Company | $686 | Royalty or License | Cash or cash equivalent | BD Pharmingen Device, Cell Analysis | 2020 | |
| 2020-12-18 | Medtronic USA, Inc. | $376 | Research payment | Cash or cash equivalent | VISUALASE Device, MRI-guided laser ablation | SLATE | 2020 |
| 2020-12-18 | Becton, Dickinson and Company | $57 | Royalty or License | Cash or cash equivalent | BD Pharmingen Device, Cell Analysis | 2020 | |
| 2020-12-18 | Becton, Dickinson and Company | $56 | Royalty or License | Cash or cash equivalent | BD Pharmingen Device, Cell Analysis | 2020 | |
| 2020-12-17 | Exelixis Inc. | $26,161 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2020 |
| 2020-12-17 | Exelixis Inc. | $22,552 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2020 |
| 2020-12-17 | Daiichi Sankyo Inc. | $20,252 | Research payment | Cash or cash equivalent | Enhertu Drug, Oncology | 2020 | |
| 2020-12-17 | Janssen Research & Development, LLC | $14,181 | Research payment | Cash or cash equivalent | A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction | 2020 | |
| 2020-12-17 | Edwards Lifesciences Corporation | $8,500 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2020 | |
| 2020-12-17 | Agios Pharmaceuticals, Inc. | $7,830 | Research payment | Cash or cash equivalent | TIBSOVO Drug, Oncology | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with | 2020 |
| 2020-12-17 | Exelixis Inc. | $4,862 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | A Randomized, Controlled Phase 3 Study of Cabozantinib XL184) in Combination with Atezolizumab versus Sorafenib in Subje | 2020 |
| 2020-12-17 | TAIHO ONCOLOGY, INC. | $3,639 | Research payment | Cash or cash equivalent | TAS3681 | 2020 | |
| 2020-12-17 | Exelixis Inc. | $3,287 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of Cabozantinib XL184) in Subjects with Radioiodine Refr | 2020 |
| 2020-12-17 | TAIHO ONCOLOGY, INC. | $2,536 | Research payment | Cash or cash equivalent | TAS3681 | 2020 | |
| 2020-12-17 | PFIZER INC. | $1,905 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A PHASE 2 OPENLABEL 2ARM RESPONSE RATE STUDY OF TALAZOPARIB IN MEN WITH DNA REPAIR DEFECTS AND METASTATIC CASTRATIONRESI | 2020 |
| 2020-12-17 | PFIZER INC. | $1,270 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A PHASE 2 OPENLABEL 2ARM RESPONSE RATE STUDY OF TALAZOPARIB IN MEN WITH DNA REPAIR DEFECTS AND METASTATIC CASTRATIONRESI | 2020 |
| 2020-12-17 | PFIZER INC. | $1,023 | Research payment | Cash or cash equivalent | FIP STUDY FOR PRMT5 | 2020 | |
| 2020-12-17 | Agios Pharmaceuticals, Inc. | $700 | Research payment | Cash or cash equivalent | TIBSOVO Drug, Oncology | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with | 2020 |
| 2020-12-17 | Becton, Dickinson and Company | $500 | Royalty or License | Cash or cash equivalent | BD Pharmingen Device, Cell Analysis | 2020 | |
| 2020-12-17 | TAIHO ONCOLOGY, INC. | $473 | Research payment | Cash or cash equivalent | TAS3681 | 2020 | |
| 2020-12-17 | PFIZER INC. | $318 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A PHASE 2 OPENLABEL 2ARM RESPONSE RATE STUDY OF TALAZOPARIB IN MEN WITH DNA REPAIR DEFECTS AND METASTATIC CASTRATIONRESI | 2020 |
| 2020-12-17 | CSL Behring | $242 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2020 | |
| 2020-12-16 | GE HEALTHCARE | $103,282 | Research payment | Cash or cash equivalent | EVALUATION OF DLIR | 2020 | |
| 2020-12-16 | E.R. Squibb & Sons, L.L.C. | $91,000 | Research payment | Cash or cash equivalent | Phase IIB Multi Tumor Viral Mediated (software expense) | 2020 | |
| 2020-12-16 | Incyte Corporation | $6,880 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-12-16 | Incyte Corporation | $3,931 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-12-16 | Intercept Pharmaceuticals, Inc. | $2,476 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2020 |
| 2020-12-16 | PFIZER INC. | $1,500 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-12-16 | PFIZER INC. | $349 | Research payment | Cash or cash equivalent | A PHASE 1 STUDY TO EVALUATE THE SAFETY PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES AND TREATMENT INTENSIFI | 2020 | |
| 2020-12-16 | Genentech, Inc. | $223 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | ATEZOLIZUMAB IN MUSCLE INVASIVE BLADDER CANCER MIBC | 2020 |
| 2020-12-15 | PFIZER INC. | $39,677 | Research payment | In-kind items and services | BESPONSA Biological, ONCOLOGY | A PHASE 4 OPENLABEL RANDOMIZED STUDY OF TWO INOTUZUMAB OZOGAMICIN DOSE LEVELS IN ADULT PATIENTS WITH RELAPSED OR REFRACT | 2020 |
| 2020-12-15 | PFIZER INC. | $12,961 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A PHASE 3 MULTICENTER MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C PLUS BEST SUPPORTIVE | 2020 |
| 2020-12-15 | PFIZER INC. | $9,712 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLY | 2020 |
| 2020-12-15 | PFIZER INC. | $6,173 | Research payment | Cash or cash equivalent | A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRAC | 2020 | |
| 2020-12-15 | Exelixis Inc. | $5,317 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2020 |
| 2020-12-15 | Bracco Diagnostics Inc. | $4,120 | Research payment | Cash or cash equivalent | MultiHance Drug, Diagnostic Imaging | An Autopsy Tissue Study For Quantification Of Gadolinium Levels And Histhopathological Changes From Subjects Who Receive | 2020 |
| 2020-12-15 | Eli Lilly and Company | $3,450 | Research payment | Cash or cash equivalent | MONARCHER-A PHASE 2, RANDOMIZED, MULTICENTER, 3-ARM, OPEN-LABEL STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS TRASTU | 2020 | |
| 2020-12-15 | Exelixis Inc. | $3,157 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2020 |
| 2020-12-15 | Exelixis Inc. | $2,600 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2020 |
| 2020-12-15 | PFIZER INC. | $2,400 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A PHASE 3 MULTICENTER MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C PLUS BEST SUPPORTIVE | 2020 |
| 2020-12-15 | Genentech, Inc. | $1,818 | Research payment | Cash or cash equivalent | ROZLYTREK Biological, BioOncology | STARTRK 2 RXDX 101 02 | 2020 |
| 2020-12-15 | Exelixis Inc. | $1,147 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2020 |
| 2020-12-15 | Exelixis Inc. | $1,138 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2020 |
| 2020-12-15 | Boston Scientific Corporation | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | GENERAL - VASCULAR ACCESS Device, VASCULAR | 2020 | |
| 2020-12-15 | Exelixis Inc. | $916 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2020 |
| 2020-12-15 | Exelixis Inc. | $887 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2020 |
| 2020-12-15 | Genentech, Inc. | $689 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | POLARIX | 2020 |
| 2020-12-15 | Exelixis Inc. | $458 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2020 |
| 2020-12-15 | Exelixis Inc. | $351 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2020 |
| 2020-12-15 | Exelixis Inc. | $246 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2020 |
| 2020-12-15 | Exelixis Inc. | $66 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2020 |
| 2020-12-14 | Bayer Healthcare Pharmaceuticals Inc. | $98,265 | Research payment | Cash or cash equivalent | Aliqopa Drug, Oncology | 060106 - Independent Research Grant (Bayer Product) | 2020 |
| 2020-12-14 | SEAGEN INC. | $59,556 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2020 | |
| 2020-12-14 | Genentech, Inc. | $56,944 | Consulting Fee | Cash or cash equivalent | Avastin Biological, BioOncology | 2020 | |
| 2020-12-14 | Genentech, Inc. | $56,944 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-12-14 | Genentech, Inc. | $56,944 | Grant | Cash or cash equivalent | Avastin Biological, BioOncology | 2020 | |
| 2020-12-14 | Genentech, Inc. | $56,944 | Grant | Cash or cash equivalent | Avastin Biological, BioOncology | 2020 | |
| 2020-12-14 | Genentech, Inc. | $56,944 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-12-14 | EMD Serono, Inc. | $34,729 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-12-14 | Edwards Lifesciences Corporation | $10,170 | Research payment | Cash or cash equivalent | PARTNER3 2015-08 | 2020 | |
| 2020-12-14 | Clovis Oncology, Inc. | $7,423 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, Hi | 2020 |
| 2020-12-14 | Janssen Research & Development, LLC | $6,909 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, Oncology | A Pilot Study of Single-Agent Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma | 2020 |
| 2020-12-14 | Gilead Sciences, Inc. | $726 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Filgotinib in Subjects with Activ | 2020 | |
| 2020-12-14 | Abbott Laboratories | $299 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2020 | ||
| 2020-12-13 | PTC Therapeutics, Inc. | $10,000 | Royalty or License | Cash or cash equivalent | 2020 | ||
| 2020-12-12 | PFIZER INC. | $1,939 | Research payment | In-kind items and services | PHASE 12A DOSE ESCALATION AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMICS AND ANTITU | 2020 | |
| 2020-12-11 | Gilead Sciences, Inc. | $65,000 | Research payment | Cash or cash equivalent | Patient-derived MDS stem cells from pluripotent stem cells | 2020 | |
| 2020-12-11 | Genentech, Inc. | $63,713 | Grant | Cash or cash equivalent | Avastin Biological, BioOncology | 2020 | |
| 2020-12-11 | Medtronic Vascular, Inc. | $15,128 | Research payment | Cash or cash equivalent | EV ICD Pivotal | 2020 | |
| 2020-12-11 | GE Global Research an unincorporated business of GE Company | $3,848 | Research payment | Cash or cash equivalent | 2020 | ||
| 2020-12-11 | Janssen Research & Development, LLC | $2,957 | Research payment | Cash or cash equivalent | BALVERSA Drug, Oncology | Erdafitinib plus Abiraterone Acetate or Enzalutamide in Double Negative Prostate Cancer | 2020 |
| 2020-12-11 | E.R. Squibb & Sons, L.L.C. | $375 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Ph III registrational study in 1L HCC nivo monotherapy | 2020 |
| 2020-12-10 | Genentech, Inc. | $63,713 | Grant | Cash or cash equivalent | Avastin Biological, BioOncology | 2020 | |
| 2020-12-10 | PFIZER INC. | $59,516 | Research payment | In-kind items and services | BESPONSA Biological, ONCOLOGY | A PHASE 4 OPENLABEL RANDOMIZED STUDY OF TWO INOTUZUMAB OZOGAMICIN DOSE LEVELS IN ADULT PATIENTS WITH RELAPSED OR REFRACT | 2020 |
| 2020-12-10 | E.R. Squibb & Sons, L.L.C. | $57,881 | Research payment | Cash or cash equivalent | Drug Interaction Database University of Washington UW Tech Transfer | 2020 | |
| 2020-12-10 | Genentech, Inc. | $56,944 | Grant | Cash or cash equivalent | Avastin Biological, BioOncology | 2020 | |
| 2020-12-10 | Genentech, Inc. | $56,944 | Grant | Cash or cash equivalent | Avastin Biological, BioOncology | 2020 | |
| 2020-12-10 | Janssen Scientific Affairs, LLC | $50,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | TAIHO ONCOLOGY, INC. | $3,534 | Research payment | Cash or cash equivalent | TAS3681 | 2020 | |
| 2020-12-10 | Incyte Corporation | $690 | Research payment | Cash or cash equivalent | Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanc | 2020 | |
| 2020-12-10 | AtriCure, Inc. | $260 | Research payment | Cash or cash equivalent | ATRICURE CRYOICE CRYOABLATION SYSTEM Device, CARDIOVASCULAR | ATRICURE CRYOICE LESIONS FOR PERSISTENT AND LONG-STANDING PERSISTENT ATRIAL FIBRILLATION TREATMENT DURING CONCOMITANT ON | 2020 |
| 2020-12-10 | AtriCure, Inc. | $60 | Research payment | Cash or cash equivalent | ATRICURE CRYOICE CRYOABLATION SYSTEM Device, CARDIOVASCULAR | ATRICURE CRYOICE LESIONS FOR PERSISTENT AND LONG-STANDING PERSISTENT ATRIAL FIBRILLATION TREATMENT DURING CONCOMITANT ON | 2020 |
| 2020-12-09 | Clovis Oncology, Inc. | $23,244 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes (LODESTAR) | 2020 |
| 2020-12-09 | SEAGEN INC. | $10,852 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 |
| 2020-12-08 | Foundation Medicine, Inc. | $74,100 | Consulting Fee | Cash or cash equivalent | FOUNDATIONONE CDX Device, ONCOLOGY | 2020 | |
| 2020-12-08 | Stemline Therapeutics Inc. | $21,232 | Research payment | Cash or cash equivalent | STML-801-0115 | 2020 | |
| 2020-12-08 | ABBVIE INC. | $7,233 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | M15-654 | 2020 |
| 2020-12-08 | Deciphera Pharmaceuticals Inc. | $4,500 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2020 |
| 2020-12-08 | Deciphera Pharmaceuticals Inc. | $3,346 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2020 |
| 2020-12-08 | Deciphera Pharmaceuticals Inc. | $2,440 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2020 |
| 2020-12-08 | Agios Pharmaceuticals, Inc. | $2,160 | Research payment | Cash or cash equivalent | TIBSOVO Drug, Oncology | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with | 2020 |
| 2020-12-08 | Incyte Corporation | $1,482 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, 2 Cohort Study of INCB050465, a PI3Kd Inhibitor, in Subjects With Relapsed or Refractory Marginal | 2020 | |
| 2020-12-08 | Agios Pharmaceuticals, Inc. | $700 | Research payment | Cash or cash equivalent | TIBSOVO Drug, Oncology | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with | 2020 |
| 2020-12-08 | Amgen Inc. | $567 | Research payment | In-kind items and services | Blincyto Biological, Oncology | R/R ALL SC Phase 1B dose finding and dose expansion cohort for efficacy. | 2020 |
| 2020-12-08 | Stemline Therapeutics Inc. | $303 | Research payment | Cash or cash equivalent | STML-801-0115 | 2020 | |
| 2020-12-08 | Deciphera Pharmaceuticals Inc. | $63 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2020 |
| 2020-12-08 | Deciphera Pharmaceuticals Inc. | $44 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2020 |
| 2020-12-08 | Deciphera Pharmaceuticals Inc. | $44 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2020 |
| 2020-12-08 | Deciphera Pharmaceuticals Inc. | $44 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2020 |
| 2020-12-08 | Deciphera Pharmaceuticals Inc. | $44 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2020 |
| 2020-12-08 | Deciphera Pharmaceuticals Inc. | $44 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2020 |
| 2020-12-08 | Deciphera Pharmaceuticals Inc. | $44 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2020 |
| 2020-12-08 | Deciphera Pharmaceuticals Inc. | $44 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2020 |
The latest 200 records of 2,336.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Seattle, WA, county King County, WA, state Washington; placed by its city name.
| Measure | Place (city or town) Seattle, WA | County King County, WA | State Washington |
|---|---|---|---|
| Population B01003 | 754,195 | 2,287,171 | 7,816,116 |
| Population, 2020 census P1 | 737,015 | 2,269,675 | 7,705,281 |
| Median age B01002 | 35.6 | 37.4 | 38.3 |
| Under 18 B01001 | 13.8% | 19.5% | 21.4% |
| 65 and over B01001 | 13.0% | 14.0% | 16.6% |
| Households B11001 | 363,466 | 941,054 | 3,064,820 |
| Foreign born B05002 | 20.2% | 25.8% | 15.4% |
| Median household income B19013 | $123,860 | $124,746 | $98,141 |
| Median family income B19113 | $188,938 | $160,840 | $118,075 |
| Per capita income B19301 | $86,095 | $74,100 | $53,744 |
| Poverty rate B17001 | 9.9% | 8.6% | 9.9% |
| Unemployment rate B23025 | 4.6% | 4.8% | 5.1% |
| Civilian labor force B23025 | 489,320 | 1,320,458 | 4,024,423 |
| Mean commute (minutes) B08013 | 26.0 | 27.6 | 26.6 |
| Bachelor's degree or higher B15003 | 68.4% | 56.7% | 39.6% |
| Housing units B25001 | 393,918 | 1,003,284 | 3,306,620 |
| Owner-occupied B25003 | 43.7% | 55.4% | 63.8% |
| Renters B25003 | 56.3% | 44.6% | 36.2% |
| Median home value B25077 | $938,600 | $859,900 | $564,600 |
| Median gross rent B25064 | $2,030 | $2,092 | $1,760 |
| White, not Hispanic B03002 | 58.8% | 52.9% | 63.1% |
| Black B03002 | 6.4% | 6.4% | 3.8% |
| Hispanic or Latino B03002 | 8.5% | 11.0% | 14.4% |
| Asian B03002 | 17.5% | 20.5% | 9.7% |
| American Indian and Alaska Native B03002 | 0.3% | 0.4% | 0.8% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Seattle, WA.
Comments